Epilep­sy and Alzheimer's cell ther­a­py biotech lays off 25% of staff

A Bay Area biotech work­ing on off-the-shelf cell ther­a­pies for epilep­sy, Alzheimer’s and oth­er undis­closed in­di­ca­tions laid off about 25% of its work­force re­cent­ly, Neu­rona Ther­a­peu­tics con­firmed to End­points News.

The pri­vate biotech, launched eight years ago out of the labs of neu­ro­sci­en­tists at UCSF, let 18 of its 68 em­ploy­ees go, a spokesper­son wrote to End­points in an emailed state­ment. Most of the af­fect­ed staffers were in­volved in re­search, the spokesper­son added, not­ing the fo­cus is on a clin­i­cal-stage as­set, with pre­clin­i­cal pro­grams paused.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.